StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for LOVE yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $15.30 | $15.47 | +1.11% | 0.1M |
| 05-19 | $15.34 | $15.18 | -1.04% | 0.1M |
| 05-20 | $15.18 | $15.65 | +3.10% | 0.1M |
| 05-21 | $15.43 | $15.84 | +2.66% | 0.1M |
| 05-22 | $16.08 | $16.16 | +0.50% | 0.1M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
The Lovesac Co designs, manufactures and sells alternative furniture which is comprised of modular couches called sactionals and premium foam beanbag chairs called sacs. It also offers other accessories such as sactional-specific drink holders, Footsac blankets, decorative pillows, fitted seat tables, and ottomans. Its products are sold across the United States through its website or company-owned retail stores which are used in homes and offices. The majority of the firm's revenue is derived from the sale of Sactionals.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2026 2026-02-01 | Q4 2025 2025-11-02 | Q3 2025 2025-08-03 | Q2 2025 2025-05-04 |
|---|---|---|---|---|
Revenue | $697.12M | $449.07M | $298.90M | $138.37M |
Operating Income | $5.36M | $-39.58M | $-23.78M | $-14.95M |
Net Income | $4.07M | $-28.04M | $-17.49M | $-10.84M |
EPS (Diluted) | $0.28 | $-1.91 | $-1.19 | $-0.73 |
Total Assets | $534.68M | $495.51M | $493.71M | $483.74M |
Total Liabilities | $315.98M | $306.21M | $296.25M | $282.53M |
Cash & Equivalents | $101.85M | $23.72M | $34.19M | $26.90M |
Free Cash Flow OCF − CapEx | $26.19M | $-52.30M | $-42.12M | $-49.95M |
Shares Outstanding | 14.62M | 14.62M | 14.60M | 14.55M |
LOVE is in the extended universe. We surface dollar-volume + price-change percentiles for every US-listed name, but the full 6-factor DNA breakdown (momentum, news, sentiment, flow, relative strength) is only computed on the curated 1137-name primary list.
DNA analysis is not available for this ticker.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.